Dark

MDWD
MediWound Ltd.
stock NASDAQ

At Close

May 9, 2025 3:59:49 PM EDT

17.56USD+0.544%(+0.10)28,295

0.00Bid 0.00Ask 0.00Spread

Pre-market

Dec 31, 1969 7:00:00 PM EST

0.00USD-100.000%(-17.46)0

After-hours

Dec 31, 1969 7:00:00 PM EST

0.00USD0.000%(0.00)0

OverviewOptionsHistoricalExchangesShortsNews

Jan 24, 2022

07:13AM EST MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers Benzinga

06:06AM EST MediWound Announces Positive Topline Results From U.S. Phase 2 Trial Of EscharEx For Debridement Of Chronic Wounds RTTNews

06:03AM EST MediWound Announces Topline Results From Its U.S. Phase 2 Trial Of EscharEx For Debridement Of Chronic Wounds; Co. Reports Primary Endpoint Met With Highly Statistically Significant Results Along With No Observed Safety Issues Benzinga

06:00AM EST Primary Endpoint Met with Highly Statistically Significant ResultsNo Observed Safety IssuesFinal Data Readout Expected in Second Quarter of 2022 GlobeNewswire Inc

Jan 5, 2022

11:16AM EST MediWound Granted European Patent Titled 'DEBRIDING COMPOSITION FOR TREATING WOUNDS' Benzinga

Dec 20, 2021

07:11AM EST MediWound Announces Positive Initial Data From Its U.S. Phase 2 Pharmacology Study Of EscharEx Showing Effective And Rapid Debridement In Chronic And Hard To Heal Wounds Benzinga

07:00AM EST Data Demonstrate EscharEx Reduces Biofilm and Bacterial BurdenEscharEx is Shown to be Safe with No Observed Safety Issues GlobeNewswire Inc

Dec 6, 2021

07:17AM EST MediWound Completes Enrollment Of Its EscharEx U.S. Phase 2 Adaptive Design Study Benzinga

07:00AM EST MediWound Completes Enrollment of its EscharEx U.S. Phase 2 GlobeNewswire Inc

Nov 18, 2021

07:37AM EST MediWound Reports European Medicines Agency Provides Regulatory Path For Its Pediatric Label Extension Of NexoBrid Benzinga

07:30AM EST EMA Provides Regulatory Path for Pediatric Label Extension for GlobeNewswire Inc

Nov 16, 2021

08:31AM EST The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment Benzinga

07:24AM EST MediWound Q3 EPS $(0.12) Beats $(0.13) Estimate, Sales $6.37M Beat $5.67M Estimate Benzinga

07:00AM EST Third Quarter Revenues of $6.4Million; Year-to-Date 2021 Revenues Increased 21% GlobeNewswire Inc

04:06AM EST Earnings Scheduled For November 16, 2021 Benzinga

Nov 15, 2021

11:22AM EST Earnings Preview For MediWound Benzinga

10:37AM EST The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More Benzinga

Nov 4, 2021

08:00AM EDT MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the third quarter ended September 30, 2021 at 7:00 am Eastern Time on Tuesday, November 16, 2021. GlobeNewswire Inc

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 4, 2021

07:37AM EDT MediWound Announces Peer-Reviewed Publication Of EscharEx In-Vivo Head-To-Head Comparator Study In The Journal Of Wound Care Benzinga

07:30AM EDT MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo GlobeNewswire Inc

Sep 3, 2021

04:14PM EDT MediWound Ltd. (Nasdaq: MDWD) (the Company), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management will present at the following investor conferences during the month of September 2021. GlobeNewswire Inc

Aug 17, 2021

12:05PM EDT Aegis Capital Maintains Buy on MediWound, Lowers Price Target to $9 Benzinga

Aug 11, 2021

06:35AM EDT HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $6.5 Benzinga

Aug 10, 2021

07:14AM EDT MediWound Q2 EPS $(0.12) Misses $(0.07) Estimate, Sales $6.10M Beat $5.63M Estimate Benzinga

07:00AM EDT Second Quarter Revenues of $6.1 Million - Increase of 50% Year-over-Year GlobeNewswire Inc

04:05AM EDT Earnings Scheduled For August 10, 2021 Benzinga

Aug 9, 2021

11:35AM EDT MediWound's Earnings: A Preview Benzinga

Aug 2, 2021

04:05PM EDT MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the second quarter ended June 30, 2021 at 7:00 am Eastern Time on Tuesday, August 10, 2021. GlobeNewswire Inc

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

07:06AM EDT MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study Benzinga

07:00AM EDT Independent Data Monitoring Committee Recommends Continuation of the Study withNoChanges to Study Sample Size GlobeNewswire Inc

Jul 26, 2021

09:36AM EDT MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer Benzinga

07:03AM EDT MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma, Expects Data Available by the End of 2021 Benzinga

07:00AM EDT MediWound Announces Initiation of U.S. Phase I/II Study of MW005 GlobeNewswire Inc

Jul 25, 2021

10:05AM EDT The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More Benzinga

Jul 20, 2021

10:27AM EDT MediWound shares were trading higher after the company announced its Phase 3 pediatric study of NexoBrid for eschar removal met its three primary endpoints with a high degree of statistical significance. Benzinga

08:19AM EDT MediWound's NexoBrid Shows Significant Beneficial Impact On Pediatric Burn Patients Benzinga

07:08AM EDT MediWound Shares To Resume Trade At 7:30 a.m. EDT Benzinga

07:01AM EDT MediWound Reports Primary Endpoints In Phase 3 Pediatric Study Trial Of NexoBrid For Eschar Removal Of Severe Thermal Burns Benzinga

07:00AM EDT MediWound Announces Positive Topline Results from Phase 3 GlobeNewswire Inc

06:57AM EDT MediWound Shares Halted News Pending Benzinga

Jul 15, 2021

08:22PM EDT Pomerantz LLP is investigating claims on behalf of investors of MediWound Ltd. (MediWound or the Company) (NASDAQ:MDWD). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Jul 9, 2021

08:05AM EDT MediWound Highlights Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published In Online Wound Repair And Regeneration Journal Benzinga

08:00AM EDT Study Findings Demonstrate Strong Results in Debriding Venous Leg Ulcers andDiabetic Foot Ulcers GlobeNewswire Inc

Jul 7, 2021

Jun 29, 2021

03:01PM EDT Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge Benzinga

12:18PM EDT Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher Benzinga

11:16AM EDT Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results Benzinga

10:57AM EDT MediWound Ltd. (MDWD) shares are down 28 percent on Tuesday morning trade after U.S. Food and Drug Administration said it determined that the biologics license application or BLA for NexoBrid cannot be approved in the present form. RTTNews

10:16AM EDT Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results Benzinga

09:23AM EDT FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop Benzinga

08:50AM EDT MediWound Shares Set To Resume At 9:15 a.m. EDT Benzinga

08:48AM EDT MediWound Shares Halted On Code News Pending Ahead Of FDA Response Press Release Benzinga

08:47AM EDT Vericel, MediWound Report That FDA Has Determined Application For MexoBrid Cannot Be Approved In Its Present Form Benzinga

08:45AM EDT MediWound Receives Complete Response Letter from U.S. FDA for GlobeNewswire Inc

08:17AM EDT The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout Benzinga

Jun 9, 2021

04:32PM EDT MediWound Says Completes Patient Enrollment For Interim Assessment Of U.S. EscharEx Phase 2 Adaptive Design Study Benzinga

04:30PM EDT MediWound Completes Patient Enrollment for Interim Assessment of GlobeNewswire Inc

Jun 7, 2021

07:00AM EDT MediWound Announces Peer-Reviewed Paper of a Case Series Report of GlobeNewswire Inc

Jun 2, 2021

10:38AM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

May 5, 2021

07:29AM EDT MediWound Expects Cash Use For 2021 To Be $5M-$7M Benzinga

07:27AM EDT MediWound Q1 EPS $(0.10) Beats $(0.11) Estimate, Sales $5.80M Beat $5.43M Estimate Benzinga

07:00AM EDT First Quarter Revenues of $5.8 Million, an Increase of 32% Year-over-Year GlobeNewswire Inc

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

May 4, 2021

10:24AM EDT MediWound Earnings Preview Benzinga

Apr 26, 2021

04:21PM EDT MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the first quarter ended March 31, 2021 at 7:00 am Eastern Time on Wednesday, May 5, 2021. GlobeNewswire Inc

Apr 22, 2021

07:34AM EDT MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx Benzinga

07:30AM EDT MediWound Enrolls First Patient in Phase 2 Pharmacology Study of GlobeNewswire Inc

Mar 24, 2021

04:05PM EDT MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that it will host an analyst day webinar on EscharEx, MediWounds enzymatic debridement agent for chronic wounds, on Tuesday, March 30, 2021 at 10am Eastern Time. GlobeNewswire Inc

Mar 2, 2021

10:57AM EST Aegis Capital Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $10 Benzinga

Feb 25, 2021

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:09AM EST MediWound Q4 EPS $(0.06) Beats $(0.11) Estimate, Sales $6.70M Beat $5.59M Estimate Benzinga

07:00AM EST Fourth Quarter Revenues of $6.7 Million- Up 23%and Full-Year 2020 Revenues of $21.8 Million- Product Revenue Up 117% GlobeNewswire Inc

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 22, 2021

06:30AM EST MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer Benzinga

06:30AM EST Phase I/II Clinical Study in Basal Cell Carcinoma Scheduled to Begin Second Quarter 2021, with Data Expected by the End of 2021 GlobeNewswire Inc

Feb 16, 2021

04:05PM EST MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2020 at 7:00 am Eastern Time on Thursday, February 25, 2021. GlobeNewswire Inc

Feb 10, 2021

04:15PM EST MediWound to Participate in the BTIG Virtual MedTech, Digital GlobeNewswire Inc

Feb 5, 2021

07:44AM EST The Daily Biotech Pulse: J&J Files For COVID-19 Vaccine Approval, Zimmer Biomet's Spin-Off, IPO Deluge Hits Street Benzinga

Jan 15, 2021

07:57AM EST The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges Benzinga

Jan 14, 2021

07:57AM EST The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates Benzinga

Jan 11, 2021

07:13AM EST MediWound Announces Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients; Interim Assessment Expected in Mid-2021 and Completion of Enrollment by Year-End 2021 Benzinga

07:00AM EST MediWound Provides Progress Update on Its EscharEx Clinical GlobeNewswire Inc

Jan 5, 2021

07:00AM EST MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10th Annual Corporate Access Event and the H.C. Wainwright BioConnect 2021 Conference. Both conferences will take place virtually. GlobeNewswire Inc

Dec 21, 2020

07:30AM EST Successful Completion of In-Vivo Head-to-Head Comparator Study of GlobeNewswire Inc

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 14, 2020

04:16PM EST MediWound Announces A Global Expansion Distribution Agreement For Its NexoBird In The United Arab Emirates With Ghassan Aboud Group Benzinga

04:15PM EST MediWound Continues Global Expansion with Distribution Agreement GlobeNewswire Inc

Nov 10, 2020

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

07:33AM EST MediWound: Q3 Earnings Insights Benzinga

07:00AM EST Total Third Quarter Revenues of $6.6 Million Increased 29% Year-over-Year GlobeNewswire Inc

Nov 2, 2020

04:01PM EST MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third quarter ended September 30, 2020 at 7:00 am Eastern Time on Tuesday, November 10, 2020. GlobeNewswire Inc

Oct 28, 2020

07:00AM EDT MediWound Completes Enrollment Stage of its NexoBrid Phase 3 GlobeNewswire Inc

Oct 14, 2020

08:00AM EDT MediWound Studying the Effect of EscharEx on Biofilm Burden GlobeNewswire Inc

Sep 23, 2020

09:33AM EDT Benzinga's Top Upgrades, Downgrades For September 23, 2020 Benzinga

06:32AM EDT BTIG Initiates Coverage On MediWound with Buy Rating, Announces Price Target of $6 Benzinga

Sep 16, 2020

07:44AM EDT MediWound Announces FDA Acceptance Of BLA For NexoBrid For Severe Thermal Burns In Adults RTTNews

07:40AM EDT MediWound Says FDA Accepted For Review Its Recently Submitted BLA For NexoBrid RTTNews

07:33AM EDT MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns Benzinga

07:30AM EDT MediWound Announces FDA Acceptance of Biologics License GlobeNewswire Inc

Sep 3, 2020

09:00AM EDT MediWound Ltd. (Nasdaq: MDWD) (the Company), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka, MediWounds Chief Executive Officer, will present at the following investor conferences in September: GlobeNewswire Inc

Aug 25, 2020

07:08AM EDT MediWound And Vericel Announce Acceptance Of First Delivery Of NexoBrid To BARDA For Emergency Response Preparedness Benzinga

07:00AM EDT MediWound and Vericel Announce Acceptance of the First Delivery of GlobeNewswire Inc

Aug 6, 2020

10:45AM EDT MediWound Earlier Reported Q2 EPS $(0.11) Beats $(0.12) Estimate, Sales $4.03M Miss $4.97M Estimate Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:01AM EDT Submitted Biological License Application to the FDA for NexoBrid EscharEx U.S. Phase 2 Study Resumed Patient Screening GlobeNewswire Inc

Jul 28, 2020

08:01AM EDT MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the second quarter ended June 30, 2020 at 7:00 am Eastern Time on Thursday, August 6, 2020. GlobeNewswire Inc

document.getElementById("D84tJm").onerror = function(){this.style.display='none';}; .dark-mode .J1Bmlq{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .J1Bmlq{ color: #333333; background-color: white; border: 2px solid #333333; }MDWDMediWound Ltd.stock NASDAQ

MDWD
MediWound Ltd.
stock NASDAQ